Disc Medicine Provides Update on Hematology Portfolio and Outlines Near-Term Business Objectives and Anticipated Milestones

Submitted a New Drug Application (NDA) for accelerated approval of bitopertin in erythropoietic protoporphyria (EPP) on September 29, 2025, and ...

Disc Medicine Inc: Disc Medicine Provides Update on Hematology Portfolio and Outlines Near-Term Business Objectives and Anticipated Milestones

Submitted a New Drug Application (NDA) for accelerated approval of bitopertin in erythropoietic protoporphyria (EPP) on September 29, 2025, and subsequently was awarded the FDA Commissioner's National ...
Investor's Business Daily on MSN

Top 1% Celcuity Shoots To Record High On Roche-Rivaling Breast Cancer Results

Celcuity stock shot a record high Monday after the company said its experimental drug delayed breast cancer progression for ...

Review & Preview: We’re Back!

I agree to the Terms of Use , Privacy Notice and Cookie Notice. I would like to receive updates and special offers from Dow Jones and affiliates. I can unsubscribe at any time.